PARP

PARP
Name	Poly(ADP-ribose) polymerase
Alt	PARP family
Caption	Representative catalytic domain

PARP Poly(ADP-ribose) polymerase is a family of enzymes involved in post-translational modification through poly-ADP-ribosylation. Members of this family participate in cellular responses to DNA damage, chromatin remodeling, and transcriptional regulation across metazoans. Research on PARP intersects work by major institutions and figures in molecular biology, clinical oncology, and pharmacology.

Introduction

PARP enzymes were characterized following biochemical studies by researchers at institutions such as Cold Spring Harbor Laboratory, Massachusetts Institute of Technology, Harvard Medical School, National Institutes of Health, and Johns Hopkins University. Seminal papers tied PARP activity to responses previously explored by scientists working on X-ray and ultraviolet radiation effects, DNA strand breakage research at Pasteur Institute, and DNA repair paradigms developed from studies at University of Cambridge and Max Planck Society. Later translational work involved collaborations with pharmaceutical companies like AstraZeneca, Pfizer, Novartis, and GlaxoSmithKline for inhibitor development.

Structure and Isoforms

PARP family members share conserved domains elucidated through structural biology groups at European Molecular Biology Laboratory, Stanford University, University of Oxford, and Scripps Research Institute. High-resolution structures from laboratories including Rutherford Appleton Laboratory and Lawrence Berkeley National Laboratory informed understanding of the catalytic domain, donor NAD+ binding site, and zinc-finger motifs. Isoforms such as PARP1, PARP2, PARP3, and tankyrase proteins were investigated in model systems maintained at Vanderbilt University, Yale University, and University of California, San Francisco. Comparative genomics projects from Broad Institute, Wellcome Trust Sanger Institute, and Genomics England highlighted conservation across species studied by groups at University of Tokyo and University of Melbourne.

Biological Functions

PARP enzymes participate in pathways first linked to cellular stress responses studied by researchers at Rockefeller University and Columbia University. Their roles include modulation of chromatin structure examined in labs at University of Chicago and King's College London, regulation of transcription factors investigated by teams at University of California, Los Angeles and University of Pennsylvania, and involvement in programmed cell death characterized in reports from Duke University and University of Pittsburgh. PARP activity intersects signaling cascades explored by investigators at Imperial College London, MIT Broad Institute, and Cold Spring Harbor Laboratory.

Role in DNA Repair and Genomic Stability

PARP1 and related isoforms act in DNA single-strand break recognition and recruitment of repair factors, a mechanism elaborated by groups at Howard Hughes Medical Institute, University of California, Berkeley, and Johns Hopkins University School of Medicine. Their interplay with homologous recombination proteins was defined alongside landmark work on BRCA1 and BRCA2 by teams at University of Pennsylvania Perelman School of Medicine, University College London, and Memorial Sloan Kettering Cancer Center. Collaboration with researchers studying ATM and ATR signaling at Cold Spring Harbor Laboratory and Fred Hutchinson Cancer Center clarified cross-talk. Studies from National Cancer Institute and European Molecular Biology Laboratory illustrated effects on genomic stability in contexts examined by investigators at Karolinska Institutet and McGill University.

Clinical Significance and Therapeutic Targeting

PARP inhibitors entered clinical development through partnerships among AstraZeneca, Clovis Oncology, Roche, and academic centers including Royal Marsden Hospital, Dana-Farber Cancer Institute, and MD Anderson Cancer Center. Trials reported by consortia at European Society for Medical Oncology, American Society of Clinical Oncology, and National Comprehensive Cancer Network established indications in tumors with defects in BRCA1 or BRCA2. Resistance mechanisms were studied by groups at University of Toronto, Cold Spring Harbor Laboratory, and University of Cologne, informing combination strategies with agents developed by Bristol-Myers Squibb and Eli Lilly and Company. PARP’s roles in inflammatory diseases attracted clinical research from Mayo Clinic, Cleveland Clinic, and Karolinska University Hospital, while neurodegenerative investigations involved teams at Massachusetts General Hospital, University College London Hospitals, and Johns Hopkins Hospital.

Detection and Measurement Methods

Assays to measure PARP activity and poly(ADP-ribose) levels were standardized in laboratories at National Institute of Standards and Technology, Centers for Disease Control and Prevention, and university core facilities at University of California San Diego and University of Washington. Techniques include immunodetection using monoclonal antibodies produced at biotechnology firms like Genentech and Abcam, mass spectrometry workflows refined at Thermo Fisher Scientific and Waters Corporation, and imaging methods developed by groups at Ohio State University and University of Queensland. Clinical pharmacodynamic assays were validated in multicenter studies involving European Medicines Agency and Food and Drug Administration regulatory frameworks, and biomarker initiatives coordinated through networks such as International Cancer Genome Consortium.

Category:Proteins